Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

This is an early-phase study testing a new type of cell therapy called CAR-T — where your own immune cells are engineered in a lab to fight cancer — for people with small cell lung cancer (SCLC) that has come back or stopped responding to treatment. **You may be eligible if...** - You have small cell lung cancer that came back or got worse after at least one round of platinum-based chemotherapy - You are between 18 and 70 years old - You are in reasonably good health overall (able to carry out light activity) - You have at least one measurable tumor outside the brain - Your HIV, hepatitis B, hepatitis C, and syphilis tests are negative - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - You have active or unstable brain metastases - You have a history of autoimmune disease (such as lupus or rheumatoid arthritis) - You had a serious infection in the past 4 weeks - You had a heart attack or stroke in the past 3 months - You have previously received DLL3-targeted therapy or any CAR-T cell therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.